BioWorld Asia

July 12, 2006

View Archived Issues

Intercell's €110M Funding Provides Exit Opportunity

Intercell AG rounded off the largest fund raising in Europe this year, with the placing of an overallotment of 1.3 million shares, bringing the total to €110.6 million (US$140.9 million). (BioWorld International) Read More

Genmab's Humax-CD20 Starts Phase III Work With NHL Focus

Read More

Breast Cancer Gene Might Mean Help For More Women

Read More

Novozymes Getting Protein Production, More From Delta

Read More

Early Funding Source To Be Provided By IP Group

Read More

Eurofins Scientific Invests In Danish, Japanese Food Firms

Read More

LTKfarma Setting Up Shop With Product In Phase I/II

Read More

Paradigm's Fourth Round: £7M For Cancer Drug Trials

Read More

Other News To Note

Read More